We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LAKE:NASDAQLakeland Industries, Inc. Analysis

Data as of 2026-04-14 - not real-time

$9.07

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Lakeland Industries (LAKE) is trading at $9.07, just below the calculated resistance of $9.35 and above the 20‑day SMA of $8.36, while the 20‑day SMA remains beneath the 50‑day SMA of $8.94, signaling a short‑term bearish bias. The RSI sits at 58.6, indicating modest momentum, and the MACD histogram is positive (0.158) despite a modestly bullish signal line, suggesting limited upside momentum. Volatility is elevated at 45% over the past 30 days and beta is 1.10, reflecting higher-than‑market price swings, and volume trends are decreasing, raising liquidity concerns. A class‑action securities‑fraud lawsuit filed in March 2026 adds a significant regulatory headwind that could pressure the stock further. Fundamentally, the company reports negative gross (34.8%) and operating margins, a trailing EPS of –$4.48, and negative cash flows, yet it carries a forward EPS of $0.21 and a forward P/E of 43.2, implying a high valuation relative to expected earnings. The price‑to‑book ratio of 0.66 and price‑to‑sales of 0.46 suggest the stock is cheap on a balance‑sheet basis, but the dividend yield of 0.8% is likely unsustainable given the earnings and cash‑flow deficits. Analysts’ consensus remains a “buy” with a median target of $15, but the confluence of technical weakness, legal risk, and weak fundamentals makes the near‑term outlook precarious.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Bearish SMA crossover and price near resistance
  • Elevated volatility and decreasing volume
  • Ongoing securities‑fraud litigation

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Negative margins and cash‑flow deficits
  • Potential upside from low price‑to‑book valuation
  • Uncertainty around legal resolution

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward EPS positivity and analyst price targets
  • Undervalued balance‑sheet metrics (P/B, P/S)
  • Possibility of operational turnaround if litigation settles

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin-19.41%
P/E Ratio43.2
ROE-28.97%
ROA-1.57%
Debt/Equity38.82
P/B Ratio0.7
Op. Cash Flow$-20977000
Free Cash Flow$-8532250

Technical Analysis

TrendBearish
RSI58.6
Support$7.15
Resistance$9.35
MA 20$8.36
MA 50$8.94
MA 200$12.45
MACDBullish
VolumeDecreasing
Fear & Greed Index87.29

Valuation

Target Price$14.75
Upside/Downside62.62%
GradeOvervalued
TypeValue
Dividend Yield0.80%

Risk Assessment

Beta1.10
Volatility45.17%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.